Big news is also expected from some of the major players; for example, Eli Lilly is aiming to conclude a phase III trial of an oral GLP-1 drug orforglipron in type 2 diabetes.

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

Developed by Eli Lilly in Indianapolis, Indiana, mazdutide is manufactured by Innovent Biologics in Suzhou, China, under an exclusive licence. Other trials are testing whether the drug can treat sleep ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.